Literature DB >> 12586568

Clonal spread of methicillin-resistant Staphylococcus aureus in a large geographic area of the United States.

M V da Silva Coimbra1, M C Silva-Carvalho, H Wisplinghoff, G O Hall, S Tallent, S Wallace, M B Edmond, A M S Figueiredo, R P Wenzel.   

Abstract

Methicillin resistance in Staphylococcus aureus has rapidly increased over the last two decades. This increase is paralleled by the emergence of unique multi-resistant MRSA clones. In Brazil, Argentina, Uruguay, Portugal and Czech Republic a specific MRSA clone is widely spread, the so-called Brazilian epidemic clone. Another epidemic clone, the Iberian clone, is disseminated in Spain, Portugal, Belgium, Scotland, Italy, Germany and New York. Thus, a large number of hospital-acquired infections have been caused by specific MRSA clones. Using different molecular techniques for MRSA typing, we verified that two unique epidemic clones are spread over large geographic area in the US. In addition, we showed that a previously described MRSA clone type, the New York clone (I::A:A), is widely spread beyond the New York frontiers. Copyright 2003 The Hospital Infection Society

Entities:  

Mesh:

Year:  2003        PMID: 12586568     DOI: 10.1053/jhin.2002.1328

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  9 in total

1.  First report of infection with community-acquired methicillin-resistant Staphylococcus aureus in South America.

Authors:  Apoena Ribeiro; Cícero Dias; Maria Cícera Silva-Carvalho; Laura Berquó; Fabienne Antunes Ferreira; Raquel Neves Soares Santos; Bernadete Teixeira Ferreira-Carvalho; Agnes Marie Figueiredo
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

2.  In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model.

Authors:  Arnold Louie; Weiguo Liu; Robert Kulawy; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

3.  Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model.

Authors:  Pamela R Tessier; Rebecca A Keel; Mao Hagihara; Jared L Crandon; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2012-02-21       Impact factor: 5.191

4.  mecA Locus diversity in methicillin-resistant Staphylococcus aureus isolates in Brisbane, Australia, and the development of a novel diagnostic procedure for the Western Samoan phage pattern clone.

Authors:  Flavia Huygens; Alex J Stephens; Graeme R Nimmo; Philip M Giffard
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

5.  Imported methicillin-resistant Staphylococcus aureus, Sweden.

Authors:  Mikael Stenhem; Ake Ortqvist; Hakan Ringberg; Leif Larsson; Barbro Olsson Liljequist; Sara Haeggman; Mats Kalin; Karl Ekdahl
Journal:  Emerg Infect Dis       Date:  2010-02       Impact factor: 6.883

6.  Prevalence and antimicrobial resistance profile of Staphylococcus in dairy farms, abattoir and humans in Addis Ababa, Ethiopia.

Authors:  Takele Beyene; Halefom Hayishe; Fikru Gizaw; Ashenafi Feyisa Beyi; Fufa Abunna; Bedaso Mammo; Dinka Ayana; Hika Waktole; Reta Duguma Abdi
Journal:  BMC Res Notes       Date:  2017-04-28

7.  Pro/con clinical debate: isolation precautions for all intensive care unit patients with methicillin-resistant Staphylococcus aureus colonization are essential.

Authors:  Barry M Farr; Geoffrey Bellingan
Journal:  Crit Care       Date:  2004-02-19       Impact factor: 9.097

8.  Cytotoxicity and enzyme inhibition studies of polyoxometalates and their chitosan nanoassemblies.

Authors:  Hamid Saeed Shah; Rami Al-Oweini; Ali Haider; Ulrich Kortz; Jamshed Iqbal
Journal:  Toxicol Rep       Date:  2014-06-06

Review 9.  The state of the science.

Authors:  Barry M Farr
Journal:  Am J Infect Control       Date:  2004-04       Impact factor: 2.918

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.